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i. Running Head
Assessment of nanomaterial BBB association and penetration
ii. Summary/Abstract
The role and functional anatomy of the blood-brain barrier (BBB) is summarized to
enable the investigator to appropriately address evaluation of nanomaterial interaction
with, and distribution across, it into brain tissue (parenchyma). Transport mechanisms
across the BBB are presented, in relation to nanomaterial physicochemical properties.
Measures and test substances to assess BBB integrity/disruption/permeation are
introduced, along with how they are used to interpret the results obtained with the
presented methods. Experimental pitfalls and misinterpretation of results of studies of
brain nanomaterial uptake are briefly summarized, that can be avoided with the
methods presented in this chapter. Two methods are presented. The in situ brain
perfusion technique is used to determine rate and extent of nanomaterial distribution
into the brain. The capillary depletion method separates brain parenchymal tissue from
the endothelial cells that contribute to the BBB. It is used to verify nanomaterial brain
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tissue entry. These methods are best used together, the latter refining the results
obtained with the former. Details of the materials and equipment needed to conduct
these methods, and description of the procedures and data interpretation, are provided.

iii. Key Words
blood-brain barrier, brain parenchyma enrichment, capillary depletion, in situ brain
perfusion, in vivo, rat
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1. Introduction
To appropriately address nanomaterial interaction with, and distribution across, the
blood-brain barrier (BBB) requires an understanding of the BBB’s roles and the
functional anatomy, physiology, and biochemistry supporting its roles. The BBB has
multiple roles. 1) It protects the brain from rapid changes in the level of some
substances in the blood that are able to penetrate the BBB and disrupt the brain, such
as amino acids. 2) It enables the distribution of some substances from blood to the brain
that are needed for brain metabolism, such as glucose and iron. 3) It greatly inhibits the
distribution of most pathogens and toxic substances, protecting the brain from their
effects while presenting a significant challenge to the intended delivery of therapeutic
agents to the brain. The anatomical components of the BBB include the brain
microvascular endothelial cells (BMECs) which line the microvessels forming the
luminal side of the BBB. They have a near total absence of fenestrations through which
substances might diffuse. BMECs differ from endothelial cells that line the vasculature
outside of the brain by their inclusion of tight junctions which are formed between
adjacent BMECs. When intact the tight junctions prevent passage of ionic substances
as small as lanthanum (hydrated ionic diameter ~ 0.8 nm) through this paracellular
barrier (1). Proteins maintain the tight junctions, providing indicators for functional BBB
alteration, including claudins, occludin, zonula occludens-1, junctional adhesion
molecules (e.g., ICAM-1), cingulin, annexin A1, VE-cadherin, PECAM-1, and laminens.
Microvessels totally perfuse the brain from within this organ (2). They are comprised of
100 billion capillaries, ~ 400 miles (600 kilometers) long, with a surface area of 20 m2 in
the human, providing a blood vessel within ~ 10 µm of every brain cell (3). They occupy
~2% of the brain volume in the cortex and a greater space in some other brain regions
3

(4,5). A basement membrane surrounds the abluminal side of the BMECs. Within the
basement membrane are pericytes that cover ~ 30% of the BMEC surface. Astrocyte
foot processes extend to cover > 90% of the abluminal BMEC surface. Neurons interact
with this complex of cells to form the neurovascular unit.

The ability of some substances to cross the BBB, whereas others are less or unable to
do so, is a function of the physicochemical properties of the substance and the
transporters and metabolic processes of the neurovascular unit, primarily in the BMECs.
Diffusion of small molecules through the BBB is a product of lipophilicity and the
reciprocal of their size (6,7), limiting lipid-mediated diffusion to small molecules that are
< ~400 Da and that form < 8 hydrogen bonds (8). This rules out nanomaterial distribution
across the intact BBB by diffusion, e.g., a 1 nm3 gold particle containing 31 atoms would
be ~ 6100 Da. Therefore, diffusion-mediated nanomaterial brain entry requires opening
the BBB tight junctions (paracellular transport) or distribution across the BMECs
(transcellular transport). The BBB can be intentionally opened by osmotic insult, e.g.,
25% mannitol infusion into a carotid artery, which provides direct delivery of blood to the
ipsilateral hemisphere. Focused ultrasound in conjunction with systemically circulating
microbubbles has also been used to open the BBB, as the ultrasound causes the
microbubbles to expand and contract, putting shear stress on the BBB. Both methods
have been used to deliver chemotherapy drugs to treat brain tumors. Conversely, BBB
opening can be an adverse effect of nanomaterials that are not intended to be delivered
to the brain.
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Although nanomaterials are unable to distribute across the intact BBB by diffusion they
have the potential to enter the brain via transcellular, carrier-mediated, transporters.
These include nutrient transporters (e.g., GLUT-1 that provides the brain with glucose
that the brain cannot generate), metal transporters (e.g., that influx iron), and receptormediated transporters, such as for transferrin and low-density lipoprotein (9). The
mechanism of nanomaterial uptake into BMECs is via clathrin-coated pit endocytosis
(10).

ATP-binding cassette transporters such as P-glycoprotein and multidrug resistance
protein inhibit brain entry by effluxing many structurally-diverse organics, including many
drugs. Metabolic processes, including peptidases, CYP 450-linked monooxygenases,
and conjugation mechanisms, also inhibit flux across the BBB.

BBB permeability in animals and/or in vitro models can be measured using substances
that do not cross the intact barrier. Historically, and currently, this has been done with
Evan’s blue. Many substances have been used, as shown in Table 1. Small markers
might indicate less extensive opening than larger ones. Some, such as sucrose, are
paracellular markers; others, such as albumin, are transcellular markers. An additional
use of these markers is as vascular volume/extracellular space markers in the in situ
brain perfusion technique (below). These markers indicate the vascular and
extracellular spaces (volume) of the perfusion fluid containing test substance
(nanomaterial), compared to the brain cellular space (test substance uptake into brain
parenchyma).
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In vitro BBB models have been extensively studied for decades (11). Their complexity
can range from cultured BMECs to co-cultures that include astrocytes, to triple cocultures that include pericytes. As complexity increases the in vivo BBB is more closely
modeled. An indicator of BBB integrity, in addition to the use of chemical permeation
markers (above), is the trans-epithelial electrical resistance (TEER) across the cells.
The TEER of immortalized BMEC monoculture is usually < 50 mΩ·cm2 (12) to 200
mΩ·cm2 (13). Monocultures of primary BMECS seldom exceed 500 mΩ·cm2 (12). A coculture of BMECs with TEER > 600 mΩ·cm2 has been described (13). The TEER of
arterial and venous vessels in 21 day and older anesthetized rats averaged 1490 and
918 mΩ·cm2, respectively, and as great as 5900 mΩ·cm2 (14). A monoculture of
human-induced pluripotent stem cells differentiated into BMECs had some TEER values
exceeding 2000 mΩ·cm2, but allowed permeation of IgG to a greater extent than seen in
mammalian brain (12), suggesting even this in vitro BBB model was not as
impermeable as the mammalian BBB.

In addition to the above chemical and electrical indicators of BBB permeability, which
indicate the pharmacokinetic integrity of the BBB as a measure of nanotoxicity, many
methods have been used to indicate toxicity to BBB anatomy and function. These
assays most commonly focus on junction proteins mentioned above; claudins, occludin,
and zonula occludens-1 (15,16), or use electron microscopy (17).

In vitro BBB models are incomplete in their cell composition, cell interactions, cell spatial
relationships, and degree of impermeability compared to the in vivo neurovascular unit.

6

Therefore, the methods described in this chapter enable the in vivo determination of
nanomaterial association with, and distribution across, the BBB with verification of brain
(parenchymal, neuropil) entry.

There have been studies addressing brain entry of many nanomaterials with the
conclusion that they get into the brain, which is different than crossing the BBB and
entering brain tissue. For most studies the methods employed were not able to confirm
nanomaterial distribution into brain parenchyma because they do not account for
nanomaterial in the blood within the brain’s vasculature or associated with BBB
components. Rats perfused to remove blood 4 h after intravenous injection of gold
glyconanoparticles had only ~4% as much nanomaterial in their brain as rats that had not
been perfused (18). Similarly, vascular perfusion reduced gold in three brain regions to 7
to 18% of that seen in non-perfused rats after intra-abdominal nanogold injection (19).
Some studies accounted for the contribution of nanomaterial in blood to brain
nanomaterial levels (5,20,21), however this does not address nanomaterial in non-brain
tissue sites such as adsorption to the luminal wall of brain vasculature or in cellular and
membrane BBB components. After intravenous injection to rodents, nanomaterials were
observed adhered to brain blood vessel walls with little to no evidence of brain tissue
entry (22-24). These observations are in agreement with a kinetic study that reported a
negatively charged nanoparticle associated with the cell surface, within seconds, by
Langmuir adsorption through electrostatic interaction (25). In several studies,
nanomaterial associated with brain at short-term time points did not persist to later times.
The rapid decline of nanomaterial within a few hours in the whole brain or brain regions,
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e.g., (19,26-33) can be interpreted as not reflecting brain tissue nanomaterial entry. This
is because it would not be anticipated that nanomaterials, once taken up by brain cells,
would be released and distribute from brain back into blood within this time. These results
suggest that not all of the nanomaterial interpreted as entering the brain distributed into
brain tissue. The nanomaterial may have adhered to the luminal wall of brain vasculature
or localized in cellular or membrane components of the BBB, and subsequently
distributed away from these sites into circulating blood and washed out of the brain. A few
reports did verify nanomaterial brain tissue entry (34,35). After whole body perfusion to
remove blood, the capillary depletion method (described below) was used to separate
brain parenchyma from brain capillaries. The percentage of the injected dose of
[111In]DTPA-multiwalled carbon nanotubes decreased in brain capillaries, but not brain
parenchyma over 24 h, providing strong evidence of brain tissue entry of this
nanomaterial (36).

The methods presented here assess whether a nanomaterial introduced into the
vasculature perfusing the brain is associated with BBB components and/or crosses the
BBB to enter brain tissue. Two methods are presented, the in situ brain perfusion
technique and the capillary depletion method. They are best used together as the
former provides a sample containing brain tissue as well as the vasculature within the
brain. The latter separates BMECs from brain parenchymal tissue. The latter method is
most often conducted with brain tissue obtained using the in situ brain perfusion
technique, but can be used with brain tissue obtained by other methods.

8

The in situ brain perfusion technique can be used to determine nanomaterial entry rate
and extent of distribution into the brain, or multiple brain regions and/or the choroid
plexus, ipsilateral to the carotid artery perfused after a short-term (few minutes or less)
intra-carotid infusion of test material. It is particularly useful for materials that rapidly
enter the brain, when the BBB has been opened intentionally, or in the presence of a
disease that alters BBB integrity such as brain cancer. The intra-carotid perfusion rate is
sufficient to prevent introduction of blood into the perfused carotid artery, therefore
preventing blood from entering the brain hemisphere perfused by that artery. This
enables control of the chemical environment of the material tested (therefore its
chemical form [speciation]), based on the perfusion fluid composition and avoidance of
exposure to blood. Avoiding blood exposure avoids potential nanomaterial
biotransformation (e.g., corona coating by plasma proteins, dissolution, or particle
breakdown) that might change its surface properties and brain uptake. Alternatively, the
influence of coating the nanomaterial with plasma proteins or any other material could
be investigated by their inclusion in the perfusion fluid.

The in situ brain perfusion technique includes the evaluation of BBB integrity based on
determination of vascular volume and extracellular space. This is accomplished by
inclusion in the perfusion fluid, by intravenous administration, or for IgG reliance on its
presence in blood, of a BBB integrity marker (Table 1) that does not significantly distribute
from blood to brain across the intact BBB during the time course of brain perfusion.
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The in situ brain perfusion technique can inform about the distribution of a nanomaterial
out of the vascular compartment. It does not differentiate association with and
distribution into BBB components from association with and uptake by brain cells.

The capillary depletion method was designed to remove the BMECs of the BBB from a
brain homogenate to identify nanomaterial that trancytosed the BBB (capillary-depleted
brain parenchyma). The goal is to determine nanomaterial distribution between the
endothelial cells that contribute to brain capillaries vs. brain parenchyma to determine
whether the nanomaterial entered brain parenchyma or if its distribution was limited to the
BMECs. It is often utilized in conjunction with the in situ brain perfusion technique, but
could be used after intravenous nanomaterial administration. The capillary depletion
method was originally described by (37). It is a gradient centrifugation method using
dextran (~ density 1.07). As a result the BMECs are in the pellet (along with brain nuclei
and erythrocytes if blood was not perfused from the brain) and the brain cells and brain
extracellular fluid are in the supernatant. Given the observed association of nanomaterials
with the luminal wall of BMECs (23,24,38) this method can help to avoid the mistaken
interpretation of results as nanomaterial brain entry, when the nanomaterial is associated
with the BMECs, not having crossed the BBB.

In the original description of the in situ brain perfusion technique the occipital and superior
thyroid arteries were coagulated or ligated and cut and the pterygopalatine artery was
ligated and cut, because these arteries do not provide blood to the brain so perfusion fluid
into the carotid artery that went into these arteries was “wasted” (39,40). Perfusion fluid
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was delivered at 4 to 5 ml/min into the external carotid artery. This rate was chosen to
minimize systemic blood flow to the contralateral hemisphere, maintain a carotid arterial
perfusion pressure above the mean systolic pressure (126 mm Hg), prevent blood from
entering the internal carotid artery from the circle of Willis, and provide a pressure below
160 to 190 mm Hg, which was shown to damage the BBB. When perfusion was to exceed
1 minute a femoral artery was cannulated to enable blood withdrawal at the same rate as
the carotid artery perfusion. There are many modifications of this method. We used a
modification developed by the senior author of the original method (37-41) that has the
advantage of being less demanding of surgical skills and can be more rapidly
accomplished (40). In this modification, the common carotid artery is cannulated followed
by ligation of the external carotid artery. Ligation of the occipital, superior thyroid, and
pterygopalatine arteries is optional. The heart is exposed and cardiac ventricles cut within
3 seconds before initiation of carotid artery perfusion. This is to terminate systemic
circulation and the potential for blood to enter the perfused hemisphere and provide an
outlet for the perfusion fluid delivered into the carotid artery. Due to perfusion fluid flow
into these common carotid artery branches that do not perfuse the brain, the rate of
perfusion fluid flow should be greater than 5 ml/min. It can be varied because there is no
systemic circulation providing an alternative blood source to the brain. Using this
modification with ligation of only the pterygopalatine artery a perfusion rate of 10 ml/min,
and without ligation of the occipital, superior thyroid, and pterygopalatine arteries, 20
ml/min was suggested (40). We used 15 and 20 ml/min flow rates that produced
comparable vascular spaces (23).

2. Materials
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2.1 Both methods
1. Ultrasonic bath/cleaner: Branson, Millipore Sigma, GT Sonic, others
2. Ability to sterilize by autoclaving, ethylene oxide, or in a glass bead dry sterilizer: Fine
Science Tools, Germinator 500, Micro Bead Sterilizer, Steri 250, others

2.2 The in situ brain perfusion technique
2.2.1 Anesthetic
1. Injectable general anesthetic:
a. Ketamine: Henry Schein animal health
b. Xylazine: Henry Schein animal health, or dexmedetomidine: Henry Schein
animal health
c. (see Note 1)
d. Plastic disposable luer-slip syringe (1 ml) and 25 g x 5/8” needle: (VWR,
others)
2. Inhalation general anesthetic: Isoflurane: Isoflurane vaporizer, supply gas, and
associated equipment
2.2.2 Equipment and supplies
1. Citranox®: Fisher Scientific, VWR
2. Absorbent pad: (VWR, others)
3. Sterile disposable drape/towel: (VWR, others)
4. Povidone-iodine (Betadine®: Fisher Scientific, VWR
5. Surgery board (optional), (see Note 2)
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6. Electric razor: Oster® Finisher® Narrow Blade Trimmer, Wahl from Braintree
Scientific and Kent Scientific Corp.
7. Homeothermic heating blanket with rectal probe: 2Biological Instruments, E-Z
anesthesia, Harvard Apparatus, Kent Scientific Corp., Stoelting
8. Scalpel handle and blade, scissors, microdissecting forceps, clamps: Fine
Science Tools, George Tiemann & Co., Roboz Surgical Instrument Co.
9. Bone rongeur, curved, ~ 2 mm cup: Fine Science Tools, George Tiemann & Co.,
Roboz Surgical Instrument Co.
10. Flat stainless steel microspatula with rounded ends: Fisher Scientific
11. Stereo boom microscope with light source: AmScope, Fisher Scientific,
Microscope.com, MicroscopeNet.com
12. 4-0 silk thread: Fine Science Tools
13. PE 50 or PE 60 tubing: Fisher Scientific, Scientific Commodities Inc., Thomas
Scientific
14. Heparin: Cardinal Health, Henry Schein animal health, Merritt, Pfizer
15. Plastic disposable luer-slip syringes, 1 and 5 ml, syringe needle, 20 gauge for
PE-60, 23 gauge for PE-50 tubing (see Note 3)
16. Syringe pump capable of delivering 5 to 20 ml/min from a 20 to 60 ml syringe:
Cole-Parmer, Harvard Apparatus Pump 11 Elite Series or earlier (11, 22, 33, 44,
PHD2000), kdScientific, New Era Pump Systems, Smiths Medical
17. Guillotine: Braintree Scientific, Nemi guillotine, or alternative method to rapidly
remove the head from the body
18. Styrofoam block with well to hold dry or liquid ice
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19. Glass plate that lays over Styrofoam block
20. Perfusion fluid: The perfusion fluid composition may depend on the experimental
goals and nanomaterial, but should be iso-osmotic, ~ pH 7.4, and 37 °C. We
used a perfusion fluid of nanomaterial containing: 153 mM Na+, 4.2 mM K+, 1.5
mM Ca2+, 0.9 mM Mg2+, 162 mM Cl-, and 9 mM glucose. Perfusion for more than
a few minutes requires addition of oxygen-carrying capacity to the perfusion fluid.
(see Note 4) This can be accomplished by addition of washed erythrocytes (40).
However, this may change the nature of the nanomaterial by association with the
erythrocytes (41-44). To determine BBB integrity, one of the BBB integrity
markers in Table 1 can be added to the in situ brain perfusion fluid or given
intravenously. Gadolinium can be quantified by elemental analysis, e.g. by ICPMS concurrently with the metal(s) of the nanomaterial if present. (see Note 5)
2.3 The capillary depletion method
2.3.1 Equipment and supplies
1. Buffer: 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM NaH2PO4, 1 mM MgSO4,
10 mM glucose, and 10 mM HEPES at pH 7.4
2. Tenbroeck tissue grinder: Fisher Scientific, Wheaton Scientific
3. Dextran 70,000 g/mol: Millipore Sigma
4. Swinging bucket refrigerated centrifuge with rotor capable of 5400 x g
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3. Methods
3.1 Both methods:
1. Clean instruments in an ultrasonic bath/cleaner after prior use.
2. Sterilize instruments.
3. Personnel should wear sterile gloves, wear proper clothing for laboratory work, and
use personal protective equipment (if needed or required).
3.2 In situ brain perfusion
3.2.1. Rat preparation
1. Deeply anesthetize the rat following, if required, a governmentally and/or
institutionally approved protocol.
a. With ketamine/xylazine (75 and 5 mg/kg) or ketamine/dexmedetomidine (50 to
75 and 0.25 mg/kg) given ip using a 25 g 5/8” needle, supplemented if necessary
with ketamine 5 mg ip, or other suitable injectable general anesthetic (see Note
1), or
b. With isoflurane (1 to 4% induction, 2 to 3% maintenance as needed), or other
suitable inhalation general anesthetic.
2. Verify sufficient depth of anesthesia by lack of response to strong tail or foot pinch.
3. Maintain body temperature, typically by a homeothermic heating blanket with rectal
probe. Alternatively maintain body temperature with a heating pad or lamp,
monitored with a rectal thermometer.
3.2.2. Prepare the surgical work site.
1. Sterilize by spraying with Citranox® followed by 70% ethanol.
2. Lay down an absorbent pad.
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3. Place a sterile disposable drape/towel containing the sterilized instruments on the
absorbent pad.
4. Drape non-procedure areas.
5. Place the anesthetized rat in dorsal recumbency (on its back). (see Note 2)
3.2.3. Cannulate the carotid artery.
1. Shave incision areas with clippers.
2. Swab incision areas with povidone-iodine.
3. Swab incision areas with 70% alcohol.
4. Expose one carotid artery (experimenter’s choice), encircle it twice with surgical
thread (4-0), one below the bifurcation, the other above, and tighten the thread on
the one below the bifurcation (cardiac side) to prevent blood flow. (see Note 6)
5. Insert sterile (see Note 7) PE 50 or PE 60 tubing containing heparin (100 U/mL)
in 0.9% NaCl into the common carotid, 4 to 5 mm above the bifurcation of the
common carotid artery and secure it in the artery by a thread knot around the
artery and indwelling tubing.
6. To contain blood released from the ligated heart, place the rat in a perfusion tray
or on a grid over a sink.
7. Expose the heart by cutting through the skin and underlying tissue with a scissors
in a caudal to rostral direction from the abdomen just below the xyphoid process
(opening the peritoneal cavity), in a mid-line incision, up through the ventral
thoracic cavity (opening it), avoiding lung, heart and mammary arteries. Cut the
right atrial chamber or vena cava with scissors.
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8. Deliver the perfusion fluid (see Note 8) using a pump and preferably a glass
syringe (see notes 9 to 16).
9. Decapitate the rat to end the perfusion.
10. Harvest the brain by cutting the scalp midline with a scalpel blade down to the
cranium and pulling the skin to the sides. Using a bone rongeur, starting at the
base of the skull, remove the skull from over the brain to expose the brain, being
careful to not remove brain tissue. Cut the dura mater with the scalpel blade and
pull it away from the brain. Use a flat stainless steel microspatula with rounded
ends to get under the brain, cut the cranial nerves, and lift the brain from the cranial
vault.
11. Place the brain sample on the cooled, moist, glass plate over the Styrofoam
block containing ice.
12. Remove the meninges and surface vessels from the brain’s surface with
microforceps.
13. Dissect the desired brain region (typically forebrain) or regions from perfused
hemisphere away from the rest of the brain and, if relevant to the brain region
isolated, remove the lateral ventricle choroid plexus from the sample. (see Note
17).
14. Retain a sample of the perfusion fluid for nanomaterial concentration analysis and
quantitation of the BBB integrity/vascular volume/extracellular space marker.
15. Quantify the nanomaterial and BBB integrity/vascular volume/extracellular space
marker in the brain sample or brain regions and perfusion fluid sample.
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3.3 The capillary depletion method
1. After nanomaterial dosing by carotid arterial perfusion of the in situ brain perfusion
technique or any other route, blood should be perfused out of the brain before the
brain is harvested. This is accomplished by systemic perfusion of the animal to
remove blood from within the brain that contains nanomaterial.
2. Homogenize the tissue in 3.5 ml ice-cold buffer with 8 to 10 strokes in a Tenbroeck
tissue grinder. Add dextran (70,000 g/mol) to 18% (w/v) and further homogenize
the sample with five additional strokes.
3. Remove an aliquot of the homogenate for determination of nanomaterial content.
4. Centrifuge the sample at 5400 x g for 15 min in a swinging bucket centrifuge at 4
ºC.
5. Carefully separate the supernatant (brain rich fraction) and pellet (capillary rich
fraction) for nanomaterial measurement in each fraction. (see Note 18)

3.4 Data analysis and interpretation of results
3.4.1. In situ brain perfusion
Flow-rate-dependent uptake is a property of some carrier-mediated transporters, but not
diffusion. To identify the process of nanomaterial brain uptake, the effect of perfusion flow
rate on influx rate can be determined. Diffusion-mediated nanomaterial brain uptake
should be concentration independent, whereas the capacity of a carrier-mediated
transporter may be exceeded. The uptake process can be further investigated by varying
the nanomaterial concentration, to determine if the uptake space (see below) becomes
saturated. This would not be expected for diffusion-mediated uptake during the short
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perfusion duration of the typical in situ perfusion experiment. Perfusion fluid flow rate- and
nanomaterial concentration-dependent brain uptake would suggest non-diffusionmediated uptake.

The influx rate (Kin) is the rate of nanomaterial influx in a given time into a given amount
(space) of brain. It is the quotient of uptake space (Q) over time. Kin reflects the volume
of perfusion fluid cleared of nanomaterial which is transferred into a specific mass
(typically expressed per gram) of brain over a given time period. It can be determined by
using multiple perfusion times, and generation of a graph of the linear least squares
regression of the corrected uptake space (Qnanomaterial) vs. perfusion time, assuming the
ANOVA of corrected uptake space vs. time shows linearity. The slope of the regression
line is an estimate of Kin. The uptake space (Qnanomaterial), or distribution volume, derived
from the in situ brain perfusion results (Qnanomaterial total), is the brain tissue mass into which
the nanomaterial distributes during a given perfusion duration. (see note 19). Qnanomaterial
total

is expressed as ml/g brain, and calculated as in eq 1 (39):

eq.1

𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦 𝐨𝐨𝐨𝐨 𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧 𝐩𝐩𝐩𝐩𝐩𝐩 𝐰𝐰𝐰𝐰𝐰𝐰𝐰𝐰𝐰𝐰𝐰𝐰 𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐛 𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭 (𝐠𝐠/𝐠𝐠)/

𝐭𝐭𝐭𝐭𝐭𝐭 𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦 𝐨𝐨𝐨𝐨 𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧 𝐩𝐩𝐩𝐩𝐩𝐩 𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯 𝐨𝐨𝐨𝐨 𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩 (𝐠𝐠/𝐦𝐦𝐦𝐦)
The uptake space is corrected for the sample’s vascular/extracellular space by
subtracting the uptake space of the vascular volume/extracellular space marker
calculated as in eq. 2 (obtained with a substance in Table 1), to give the corrected uptake
space, calculated as in eq 3, and used to calculate Kin.
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eq.2

𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯/𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬 𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦 (𝐠𝐠/𝐠𝐠) / 𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯/

𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬 𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦 𝐩𝐩𝐩𝐩𝐩𝐩 𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯 𝐨𝐨𝐨𝐨 𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐩𝐚𝐚𝐭𝐭𝐭𝐭 (𝐠𝐠/𝐦𝐦𝐦𝐦)

eq.3

𝑸𝑸𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧 = 𝑸𝑸𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧 𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭 –

𝑸𝑸𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯𝐯/𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬 𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦𝐦

3.4.2. The capillary depletion method
The percentage of nanomaterial in the capillary-enriched fraction is determined as:
(nanomaterial mass in the capillary-enriched fraction normalized to the whole brain /
nanomaterial mass in the homogenized brain aliquot normalized to the whole brain) x
100%.

Mass balance can be calculated by comparing the sum of the nanomaterial in the
capillary-enriched fraction normalized to the whole brain (or brain sample) plus
nanomaterial in the capillary-depleted-fraction normalized to the whole brain (or brain
sample), compared to the nanomaterial in the aliquot of the homogenized brain
normalized to the whole brain (or brain sample).
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4. Notes
1. There are now and will be in the future many suitable alternatives to this
combination.
2. The operator may want to restrain the rat on a surgery board: Harvard
Apparatus, Plas-Labs, Inc.
3. Dull the tip of needles to be inserted into PE tubing to reduce sticking oneself
with the needle and puncturing the tubing while inserting the needle in the tubing.
This can be done with a file, being careful to not occlude the needle lumen.
Inserting stainless steel wire in the needle lumen helps avoid occlusion. The
inner diameter of a 20 gauge needle is 0.34 mm and of a 23 gauge needle is 0.6
mm.
4. Introducing oxygen-carrying capacity to the perfusion fluid can be accomplished
by addition of washed erythrocytes (40) or blood substitute. However, erythrocyte
association may change the nature of the nanomaterial (41-44).
5. Sucrose, and perhaps some of the other markers, is a source for microorganism
metabolism. If not maintained sterile it can be catabolized and the results of its
use to determine the vascular space would not be valid.
6. Some videos showing carotid artery isolation are available:
https://www.bing.com/videos/search?q=youtube+of+rat+carotid+artery+cannulati
on&view=detail&mid=5C689127E36E8933C4AA5C689127E36E8933C4AA&FO
RM=VIRE; https://www.youtube.com/watch?v=a_cdEJHRiVs;
https://www.youtube.com/watch?v=QoGmUSOJSoM;
https://www.jove.com/video/51881/catheterization-carotid-artery-jugular-vein-toperform-hemodynamic
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7. PE tubing can be sterilized by ethylene oxide or 70% ethanol immersion.
Autoclaving should not be used as it melts the tubing. Tubing insertion into the
carotid artery was facilitated when the artery was partially cut at an angle and the
tubing end was beveled.
8. Following at least 1 h incubation at 37 °C, the perfusion fluid is bubbled for 2
minutes with 95/5 air/CO2 and adjusted to pH 7.4. The perfusion fluid should be
used as soon as possible, at 37 °C. Maintained at 37 °C perfusion fluid pH was
shown to be stable for 4 h (45).
9. Delivery of perfusion fluid in the in situ brain perfusion technique is best
accomplished using glass, rather than plastic syringes, due to lower friction of the
former. Sources of glass syringes and plungers include Becton Dickinson,
Hamilton 1000 series gastight syringe, Harvard Apparatus Yale Glass Syringe
with Robb Tip, Leur-Loc.
10. Nanomaterials rapidly associate with proteins in blood. Protein coating, the
corona, can greatly influence the nanomaterial surface properties, and “what the
cell sees” (46). The use of a blood/plasma/serum-free perfusion fluid delivering
the nanomaterial to the brain in the in situ brain perfusion procedure reduces the
potential for significant change to its surface chemistry, compared to its delivery
to the brain in blood or blood components. Uncoated nanomaterials tend to
rapidly agglomerate in the presence of ions in the surrounding solution.
Nanomaterials are typically surface coated to reduce agglomeration. When the in
situ brain perfusion procedure is used it would be wise to determine if the
nanomaterial agglomerates in the perfusion fluid during its exposure time.
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11. If there is concern that nanomaterial properties would be significantly affected by
contact with blood at the beginning of the perfusion, nanomaterial-free perfusion
fluid could be delivered before initiation of nanomaterial-containing perfusion
fluid.
12. The duration of in situ perfusion is generally no more than 2 minutes to avoid
anoxic injury to the BBB and brain, unless an oxygen-providing source is added to
the perfusion fluid. (see Note 4)
13. The “dead” volume of the carotid infusion cannula that is not filled with
nanomaterial-containing perfusion fluid that will be delivered to the brain before the
nanomaterial-containing perfusion fluid must be considered when determining the
infusion time and amount of nanomaterial delivered to the brain. One approach is
to add sufficient time to the perfusion to displace the non-nanomaterial-containing
perfusion fluid and to deliver the entire intended volume of test substancecontaining perfusion fluid. A better approach is to deliver the entire volume of test
substance in perfusion fluid to the brain then follow its infusion with nanomaterialfree perfusion fluid, as discussed in the next note.
14. After perfusion fluid administration, cerebrovascular washout of the perfusion fluid
should be conducted to remove the contribution of nanomaterial in the vascular
space to apparent brain uptake. This can be conducted by perfusion of
nanomaterial-free perfusion fluid for 5 to 20 seconds at the same rate as used to
deliver the perfusion fluid, immediately following perfusion of the nanomaterialcontaining perfusion fluid.(47)
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15. The rapid change from nanomaterial-containing to nanomaterial-free perfusion
fluid can be accomplished with a 4-way stopcock, e.g. BD M4018, BD 394910, B.
Braun 455991, B. Braun 456003, B. Braun 457501.
16. For small molecules that might back diffuse from brain to blood, or substances
that might be transported in that direction after entering the brain, efflux will
reduce apparent brain uptake. The longer the time before decapitation including
perfusion duration, the greater the potential for efflux. For nanomaterials, that are
not expected to be released from cells after their uptake by phagosomes and
incorporation into phagolysosomes, this should not be a concern.
17. Specific brain regions can be harvested by sectioning the brain in an acrylic
matrice (Braintree Scientific, Inc.) to 1 mm thick sections with a razor blade and
placing the sections on the glass plate over ice in the well of a Styrofoam block.
Ice keeps the glass cold and moist, avoiding brain sticking to the glass. Specific
brain regions can be dissected from the slices with guidance from a rat brain
atlas (e.g., (48), http://labs.gaidi.ca/rat-brain-atlas/). When regional variation is to
be studied, brain tissue is often collected from the frontal cortex, parietal cortex,
occipital cortex, thalamus/hypothalamus, midbrain/colliculus, striatum,
cerebellum, hippocampus, and choroid plexus. The weight of each sample is
obtained in a pre-weighed vessel.
18. The separation should produce much higher activity of alkaline phosphatase and
g-glutamyltransferase activity, capillary-specific enzymes, in the capillaryenriched fraction. They can be determined using enzyme activity kits (Millipore

24

Sigma). Microscopic examination should also confirm the presence of capillary
fragments in the capillary-enriched fraction, but not the capillary-poor fraction.
19. An increase of Qnanomaterial with increased duration of perfusion indicates
nanomaterial association with BMECs and/or brain entry. It does not
unequivocally demonstrate brain parenchyma entry. To determine this, the
capillary depletion method can be used. One alternative to the capillary depletion
method to confirm brain parenchyma nanomaterial uptake for electron dense
nanomaterials is electron microscopy (and for metal-containing nanomaterials
elemental analysis, such as energy-dispersive X-ray spectroscopy), to
qualitatively demonstrate brain parenchyma uptake.
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Table 1. Substances to quantify BBB permeability (or its reciprocal, integrity) and to
determine the volume of the vascular and extracellular spaces of the perfusion fluidcontaining test substance (nanomaterial) in harvested brain tissue. The table lists
substances in ascending order of their size and some commonly used quantification
methods.
Substance

3H-

Size (Da)

or 14C-α-amino
isobutyric acid

103

3H-

182

or D-[1-14C] mannitol

fluorescein

334

Concentration in
intra-carotid
perfusion fluid1
Intravenous
concentration or
dose2
3H 1 or 14C 0.5
µCi/ml1
14C 10 to 80 µCi2 (49,
50)
3H 1 or 14C 0.5
µCi/ml, 10 µCi 1
(51,52)
3H 15 µCi2 (53)
0.1%1 (54)
0.1%2 (55)
3H

3H-

or U-14C-sucrose

lucifer yellow
gadoliniumdiethylenetriamine
pentaacetic acid
(DTPA) complex
3H-

or U-14C-inulin

carboxyl-[14C]-inulin
horseradish peroxidase

342
457
938

Radiation counting

Radiation counting
Fluorescence (excitation
λmax 493 nm, emission
λmax 514 nm)

1 or 14C 0.5
µCi/ml1
14C 10 to 80 µCi2 (49,
Radiation counting
56)
5 mM1 (57)
Fluorescence (excitation
2
25 mg (58)
λmax 380 nm, emission
λmax 542 nm)
0.6 mmol/kg1 (59)
0.4 mmol/kg2 (51)

~ 6200

1 or 14C 0.5
µCi/ml1 (39)
3H 30 to 50 µCi2
(56,60)
14C 4 µCi2 (53)
0.5 µCi/ml1

44,000

2.5 mg/min1 (61)
34 mg/kg2 (62)

~ 50005500

Quantification
method(s)

MRI or Gd ICP-MS
elemental analysis

3H

36

Radiation counting
Radiation counting
Forms a brown reaction
product with
diaminobenzidine (λmax
465) or a blue product
with o-dianisidine (λmax
460 nm)

Evan’s blue + albumin
complex
~ 66,000
FITC-albumin

FITC-dextran
3H-

or 14C-dextran

Alexa488-labeled IgG
biotinylated IgG
IgG

VIS spectroscopy (λmax
0.1% Evan’s
609, 635 nm; Evan’s
(54)
blue)
2
2% Evan’s blue
immunocytochemistry
(63,64)
(albumin)
Fluorescence (excitation
10 mg/min1 (65)
λmax 495 nm, emission
2
28 to 56 mg/kg (66) λmax 525 nm)
Immunohistochemistry
2
5 to 750 mg/kg (63, Fluorescence (excitation
67,68)
λmax 492 nm, emission
λmax 518 nm)
3H 1 or 14C 0.5
µCi/ml1
Radiation counting
3H 30 µCi2 (56)
14C 4 µCi2 (53)
Fluorescence (excitation
2
10 mg/kg (69)
λmax 490 nm, emission
λmax 525 nm)
2
28 mg/kg (66)
Immunohistochemistry
Endogenous in blood Immunohistochemistry
blue1

Variable,
70,000
typically
used

155,000
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